Neovasculgen is a gene therapy drug for treatment of PAD – Peripheral Arterial Disease. The drug successfully passed all clinical trials in Russia and has proven to be 3-5 times more effective than any other treatment. To date more than 3000 patients treated and no SAEs observed. Clinical trials results are published in 3 US peer-reviewed journals.